RUNX1 and acute myeloid leukemia: The analysis of AML progression samples on gilteritinib treatment demonstrated that gilteritinib therapy was able to reduce the major clones in the AML diagnosis sample (C2, C3, C4, and C5) characterized by TET2 and RUNX1 mutations, with or without the FLT3-TKD mutation.